Limited Competition for the Continuation of the Assessment, Serial Evaluation and Subsequent Sequelae of Acute Kidney Injury (ASSESS AKI) Study (U01)

The summary for the Limited Competition for the Continuation of the Assessment, Serial Evaluation and Subsequent Sequelae of Acute Kidney Injury (ASSESS AKI) Study (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition for the Continuation of the Assessment, Serial Evaluation and Subsequent Sequelae of Acute Kidney Injury (ASSESS AKI) Study (U01): The purpose of this limited competition is to extend the activities of the ASSESS AKI consortium to continue an observational cohort of patients with normal renal function and with chronic kidney disease (CKD) who have had an episode of AKI and appropriate control participants to ascertain a) long-term renal functional outcomes, b) long-term cardiovascular disease outcomes, c) quality of life and cognitive functional outcomes, and d) survival. In addition, the utility of putative biomarkers to predict short and long-term outcomes will be assessed. The extension will insure the statistical power and the significance of the study outcomes. The extension will insure the statistical power and significance of the study outcomes. The ASSESS AKI is comprised of three Participating Clinical Centers (PCCs) and a data Coordinating Center. An additional site was added as an ancillary study in 2010.